Current Report Filing (8-k)
11 5월 2023 - 7:07PM
Edgar (US Regulatory)
0001847846
false
0001847846
2023-05-11
2023-05-11
0001847846
EUDA:OrdinarySharesMember
2023-05-11
2023-05-11
0001847846
EUDA:RedeemableWarrantsMember
2023-05-11
2023-05-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 11, 2023 (May 11, 2023)
EUDA
Health Holdings Limited
(Exact
Name of Registrant as Specified in its Charter)
British
Virgin Islands |
|
001-40678 |
|
n/a |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
1
Pemimpin Drive #12-07
One
Pemimpin Singapore 576151
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: +65 6268 6821
n/a
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Ordinary
Shares |
|
EUDA |
|
NASDAQ
Stock Market LLC |
|
|
|
|
|
Redeemable Warrants |
|
EUDAW |
|
NASDAQ Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 |
Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
At
a duly held meeting (the “Meeting”) of the Board of Directors (the “Board”) of EUDA
Health Holdings Limited (the “Company”) on May 11, 2023, the Board approved a vote to remove David Capes as
a director of the Company effective immediately. Prior to his removal, Mr. Capes served as Chairman of the Board, Chairman of the Audit
Committee, and Chairman of the Corporate Governance and Nominating Committee. As a result of his removal as a director, Mr. Capes was
also removed (i) as Chairman of the Board, (ii) as Chairman and member of the Audit Committee, and (iii) as Chairman
and member of the Corporate Governance and Nominating Committee.
The
circumstances that led to the removal of Mr. Capes as a director include the failure to follow and adhere to proper corporate formalities
in calling, holding and presiding over meetings of the Board in accordance with the Company’s Amended and Restated Memorandum and
Articles of Association and British Virgin Islands corporate law.
The
Company has provided Mr. Capes with a copy of the disclosures made in this Current Report on Form 8-K (this “Form 8-K”).
Further, the Company has provided Mr. Capes with the opportunity to furnish to the Company as promptly as possible a letter addressed
to the Company stating whether he agrees with the statements made by the Company in this Form 8-K and, if not, stating the respects in
which he does not agree. The Company will file any letter received by the Company from Mr. Capes as an exhibit by amendment to this Form
8-K within two business days after any such letter is received.
At
the Meeting, the Board appointed Mr. Lew Chern Yong (Eric) as Chairman of the Board, member and Chairman of the Audit Committee,
and Chairman of the Corporate Governance and Nominating Committee, which appointments Mr. Lew accepted effective immediately.
As
a result, the composition of the Board committees are as follows:
|
● |
The Audit Committee consists of Eric Lew (Chairman),
Alfred Lim, and Leonard Chia. |
|
● |
The Corporate Governance and Nominating Committee consists
of Eric Lew (Chairman), Alfred Lim, and Leonard Chia. |
|
● |
The Compensation Committee consists of Alfred Lim (Chairman),
Eric Lew, and Leonard Chia. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
May 11, 2023
|
EUDA Health
Holdings Limited |
|
|
|
|
By: |
/s/ Wei
Wen Kelvin Chen |
|
Name: |
Wei Wen Kelvin Chen |
|
Title: |
Chief Executive Officer |
8i Acquisition 2 (NASDAQ:LAXXU)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
8i Acquisition 2 (NASDAQ:LAXXU)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024